- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00463619
Follow-up Study With Retarded Release Phosphatidylcholine in Ulcerative Colitis
Follow-Up Study with Retarded Release Phosphatidylcholine in Ulcerative Colitis
Objectives:
The objective of the study is to evaluate the follow up of patients treated with retarded release phosphatidylcholine in three controlled, randomized studies.
Main question is to investigate whether treatment with phosphatidylcholine could spare patients the intake of steroids and immunosuppressants without clinical deterioration.
Study population:
- Retarded release phosphatidylcholine in chronic-active ulcerative colitis.
- Retarded release phosphatidylcholine in steroid dependent ulcerative colitis.
- Dose finding study for retarded release phosphatidylcholine
Outcome parameters:
Definition of remission:
- SCCAI <2,5
- Likert scale: grade 1 or 2
- subjective impression of remission: yes/no
- no blood in stool
Definition of relapse:
- subjective impression: yes/no
- SCCAI ≥ 5
- blood in stool
Definition of low clinical activity: SCCAI < 5
Primary endpoint:
sparing effect of steroids and/or immunosuppressants by rPC in chronic active UC.
Secondary endpoints
- maintenance of continuous remission
- improvement of disease activity: a. clinical activity (SCCAI) b.life quality (SIBDQ-D) c.Likert Score
- relapse rate: a. time to first relapse b. clinical activity during relapses c. number of relapses in relation to length of treatment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69120
- University Heidelberg - Dep. Gastroenterology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients from previous studies with retarded release phosphatidylcholine
Exclusion Criteria:
- patients with less then 6 weeks follow-up after end of initial study
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Max Karner, MD, University Heidelberg - Gastroenterology
- Principal Investigator: Verena Schmieg, Cand. med., Heidelberg University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AVT123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Retarded release phosphatidylcholine
-
Heidelberg UniversityDietmar Hopp Stiftung; Prof. Wolfgang StremmelCompleted
-
Heidelberg UniversityDietmar Hopp StiftungWithdrawnUlcerative ColitisGermany
-
Heidelberg UniversityDietmar Hopp Stiftung; Professor Wolfgang StremmelCompletedUlcerative Colitis | PhosphatidylcholineGermany
-
University of Colorado, DenverWithdrawnSchizophrenia | Diminished P50 Sensory GatingUnited States
-
Drug Induced Liver Disease Study GroupBeijing Union Pharmaceutical FactoryCompletedDrug-Induced Acute Liver InjuryChina
-
ARCAGY/ GINECO GROUPRecruitingOvarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer Stage IIIbFrance
-
National Center for Research Resources (NCRR)UNC Lineberger Comprehensive Cancer CenterCompletedMetabolism, Inborn Errors | Methionine Adenosyltransferase Deficiency
-
Drug Induced Liver Disease Study GroupBeijing Union Pharmaceutical FactoryRecruitingDrug-Induced Acute Liver InjuryChina
-
AMIpharm Co., Ltd.CompletedModerate or Severe Submental FullnessKorea, Republic of
-
AMIpharm Co., Ltd.CompletedModerate or Severe Submental FullnessKorea, Republic of